Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.98M | -4.29M | -6.60M | -9.38M | -12.17M |
| Total Depreciation and Amortization | 3.40K | 7.50K | 11.60K | 11.60K | 11.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.37M | -1.04M | 278.80K | 251.60K | 224.40K |
| Change in Net Operating Assets | 77.60K | 1.23M | 2.39M | 2.32M | 2.25M |
| Cash from Operations | -4.27M | -4.09M | -3.92M | -6.80M | -9.68M |
| Capital Expenditure | -4.00K | -2.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -4.00K | -2.00K | -- | -- | -- |
| Total Debt Issued | -- | 816.90K | 1.63M | 1.63M | 1.63M |
| Total Debt Repaid | 0.00 | -97.40K | -194.80K | -97.40K | -- |
| Issuance of Common Stock | 5.43M | 3.40M | 1.38M | 690.10K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -386.40K | -193.20K | -- | -- | -- |
| Cash from Financing | 5.04M | 3.93M | 2.82M | 2.23M | 1.63M |
| Foreign Exchange rate Adjustments | -- | 200.00 | 400.00 | 200.00 | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 767.60K | -165.60K | -1.10M | -4.57M | -8.05M |